+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy



A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy



American Journal of Kidney Diseases 37(4): 847-851



The chelator somatostatin analogue dota-D-phe(1)-tyr(3)-octreotide (DOTATOC), which is stably labeled with the beta-emitting radioisotope yttrium 90 ((90)Y), is used as internal radiotherapy for the treatment of patients with advanced neuroendocrine tumors. We report 5 patients who developed chronic renal failure, caused in 3 patients by biopsy-proven thrombotic microangiopathy (TMA). Twenty-nine patients (14 men, 15 women) with normal renal function before therapy were treated with divided intravenous doses of (90)Y-DOTATOC approximately 6 weeks apart (mean normalized cumulative dose, 165.4 +/- 36.4 mCi/m(2)). Twenty-two of 29 patients were administered a normalized cumulative dose of 200 mCi/m(2) without side effects. Among the 7 patients (6 women, 1 man) administered a normalized cumulative dose greater than 200 mCi/m(2), 5 patients (4 women, 1 man) developed renal failure. Increasing serum creatinine levels were observed within 3 months after the last (90)Y-DOTATOC injection. The evolution was rapidly progressive in 3 patients, resulting in end-stage renal failure within 6 months. The remaining 2 patients developed chronic renal insufficiency (mean serum creatinine level, 300 micromol/L an average 16 months after the end of treatment). Renal biopsies performed in 3 patients showed typical signs of TMA involving glomeruli, arterioles, and small arteries. Patients treated with high-dose (90)Y-DOTATOC internal radiotherapy (cumulative dose > 200 mCi/m(2)) are at high risk to develop severe renal failure caused by TMA lesions. The histopathologic lesions are identical to those found after external radiotherapy, which suggests a causal relationship between (90)Y-DOTATOC and renal TMA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045079308

Download citation: RISBibTeXText

PMID: 11273886

DOI: 10.1016/s0272-6386(01)80135-9


Related references

De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. American Journal of Kidney Diseases 41(2): 471-479, 2003

Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet. Haematology 3(5): E237-E245, 2016

Internal medicine diseases and anti-thrombotic therapy. Angiitis and thrombotic microangiopathy - mainly for the kidney. Nihon Naika Gakkai Zasshi 86(9): 1634-1638, 1997

Is it possible to diagnose primary anti-phospholipid syndrome on the basis of renal thrombotic microangiopathy in the absence of other thrombotic process?. Renal Failure 25(6): 1043-1049, 2003

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer 45(3): 365-371, 2004

Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings 91(9): 1189-1211, 2016

Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Molecular Imaging and Biology 16(4): 586-594, 2014

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. European Journal of Nuclear Medicine 26(8): 877-886, 1999

Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Quarterly Journal of Medicine 68(258): 795-815, 1988

Acute renal failure and severe hypertension in children with renal thrombotic microangiopathy. Nephron 66(3): 302-306, 1994

Acute renal failure in a renal allograft: an unusual infectious cause of thrombotic microangiopathy. American Journal of Kidney Diseases 46(1): 159-162, 2005

Systemic and renal fibrinolytic activity in a patient with anticardiolipin syndrome and renal thrombotic microangiopathy. American Journal of Nephrology 10(3): 254-258, 1990

Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. Journal of the American Society of Nephrology 10(1): 146-153, 1999

Reversible renal failure due to the antiphospholipid antibody syndrome, pre-eclampsia and renal thrombotic microangiopathy. Clinical Nephrology 44(4): 271-273, 1995

Renal Thrombotic Microangiopathy. Boletin Medico del Hospital Infantil de Mexico 21: 691-698, 1964